Fallopian Tube Cancer: Causes, Symptoms, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Primary fallopian tube carcinoma is a rare gynecologic malignancy representing approximately 1-2% of all gynecologic cancers. Most are high-grade serous carcinomas arising from the fimbriated end of the fallopian tube and are biologically indistinguishable from BRCA-associated high-grade serous ovarian carcinoma. Current evidence suggests the fallopian tube is the origin site for many cases previously classified as ovarian cancer. The FIGO classification combines staging for ovarian, fallopian tube, and primary peritoneal carcinomas.

BRCA1 (up to 60% lifetime risk) and BRCA2 (10-30% lifetime risk) germline mutations are the most important risk factors. Lynch syndrome also confers elevated risk. Nulliparity, infertility, early menarche, late menopause, and postmenopausal hormone replacement therapy increase risk. Oral contraceptive use and parity are protective factors. Salpingitis and chronic pelvic inflammatory disease may predispose in a subset of cases. The majority of cases are sporadic without identified hereditary predisposition.

Most patients are postmenopausal (median age 55-60 years) with presenting symptoms including abnormal uterine bleeding, pelvic pain, adnexal mass, and abdominal distension from ascites. Hydrops tubae profluens (intermittent profuse watery vaginal discharge) is pathognomonic but rare. CA-125 is elevated in approximately 80% of cases. Many cases are diagnosed at an advanced stage due to nonspecific symptoms and peritoneal spread pattern.

Transvaginal ultrasound identifies adnexal mass or complex tubal structure; CT and MRI define tumor extent. CA-125, HE4, and ROMA score supplement imaging for risk stratification. Definitive diagnosis requires surgical histopathology; primary tubal origin is established when the tumor mass is located in the fallopian tube, the histological transition from benign to malignant tubal epithelium is identified, and the ovaries and uterus are uninvolved or involvement is minimal. FIGO 2014 staging applies.

Primary cytoreductive surgery (total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic and para-aortic lymphadenectomy, and peritoneal cytoreduction to no residual disease or less than 1 cm) followed by carboplatin plus paclitaxel for 6 cycles is the standard approach. Bevacizumab is added for Stage III-IV disease. BRCA-mutant patients receive maintenance olaparib for up to 2 years after achieving response to platinum-based chemotherapy. Neoadjuvant chemotherapy followed by interval debulking is used for patients unsuitable for primary surgery.

Five-year survival by FIGO stage: Stage I approximately 85-90%, Stage II approximately 50-70%, Stage III approximately 25-40%, Stage IV approximately 10-20%. Outcomes are closely comparable to high-grade serous ovarian carcinoma with similar stage and treatment. BRCA1/2-mutant cancers respond better to platinum and PARP inhibitors, with improved progression-free and overall survival compared to BRCA wild-type. Maintenance olaparib in BRCA-mutant disease improves median PFS from 13.8 to 51.8 months (SOLO-1 trial).

Prophylactic bilateral salpingo-oophorectomy is strongly recommended for BRCA1 mutation carriers by age 35-40 and BRCA2 carriers by age 40-45, reducing gynecologic cancer risk by approximately 96%. Oral contraceptives reduce overall risk by approximately 40% with 5+ years of use. Lynch syndrome patients benefit from annual gynecologic surveillance and prophylactic hysterectomy and salpingo-oophorectomy after childbearing is complete. No effective population-level screening test exists; serum CA-125 and transvaginal ultrasound have not been proven to reduce mortality in the general population.